MX2020004683A - Metodos de inmunoterapia oral. - Google Patents
Metodos de inmunoterapia oral.Info
- Publication number
- MX2020004683A MX2020004683A MX2020004683A MX2020004683A MX2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A
- Authority
- MX
- Mexico
- Prior art keywords
- peanut
- peanut allergy
- subject
- treatment
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 11
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 206010016946 Food allergy Diseases 0.000 abstract 7
- 208000008267 Peanut Hypersensitivity Diseases 0.000 abstract 7
- 201000010853 peanut allergy Diseases 0.000 abstract 7
- 235000017060 Arachis glabrata Nutrition 0.000 abstract 3
- 241001553178 Arachis glabrata Species 0.000 abstract 3
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract 3
- 235000018262 Arachis monticola Nutrition 0.000 abstract 3
- 235000020232 peanut Nutrition 0.000 abstract 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract 1
- 229930182837 (R)-adrenaline Natural products 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 229960005139 epinephrine Drugs 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580999P | 2017-11-02 | 2017-11-02 | |
| US201862631406P | 2018-02-15 | 2018-02-15 | |
| US201862637903P | 2018-03-02 | 2018-03-02 | |
| US201862674478P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/058777 WO2019089978A1 (en) | 2017-11-02 | 2018-11-01 | Methods of oral immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004683A true MX2020004683A (es) | 2020-08-13 |
Family
ID=66332382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004683A MX2020004683A (es) | 2017-11-02 | 2018-11-01 | Metodos de inmunoterapia oral. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11369676B2 (https=) |
| EP (1) | EP3703743A4 (https=) |
| JP (1) | JP7498661B2 (https=) |
| KR (1) | KR102753602B1 (https=) |
| CN (1) | CN111344010A (https=) |
| AU (1) | AU2018358125B2 (https=) |
| CA (1) | CA3080601A1 (https=) |
| MX (1) | MX2020004683A (https=) |
| WO (1) | WO2019089978A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| WO2014159607A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
| AU2015306683B2 (en) | 2014-08-25 | 2021-11-25 | Societe Des Produits Nestle S.A. | Egg protein formulations and methods of manufacture thereof |
| EP4545077A1 (en) | 2017-12-06 | 2025-04-30 | Prollergy Corporation | Composition and method for reducing allergic response |
| US11406563B2 (en) | 2018-07-27 | 2022-08-09 | Société des Produits Nestlé S.A. | Oral immunotherapy unit dose dispensing systems and methods |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| WO2020100024A1 (en) * | 2018-11-12 | 2020-05-22 | Murdoch Childrens Research Institute | Method and system |
| CA3123605A1 (en) | 2018-12-20 | 2020-06-25 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy dosing schedule for missed doses |
| EP3965815A4 (en) * | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| CA3162040A1 (en) * | 2019-12-23 | 2021-07-01 | Bronwyn POLLOCK | Pharmaceutical compositions |
| AU2020412960A1 (en) * | 2019-12-23 | 2022-06-16 | Prota Therapeutics Pty Ltd | Allergy treatment |
| BR112022026945A2 (pt) | 2020-07-01 | 2023-03-07 | Nestle Sa | Determinação de equipe médica para imunoterapia oral |
| WO2022089595A1 (en) * | 2020-10-30 | 2022-05-05 | Oneness Biotech Co., Ltd. | Biomarkers for ige-mediated diseases |
| JP2024509087A (ja) * | 2021-02-24 | 2024-02-29 | オールアダプト イミュノセラピューティクス，インコーポレイテッド | アレルギーの治療方法 |
| US20250342925A1 (en) * | 2022-04-15 | 2025-11-06 | Samsung Life Public Welfare Foundation | Method for providing food allergy treatment service using oral immunotherapy, computer program stored in recording medium to implement method, and system |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809767A (en) | 1969-05-12 | 1974-05-07 | Griffith Laboratories | Methods of making vegetable protein concentrates |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
| US20090111702A1 (en) | 2004-04-06 | 2009-04-30 | Mount Sinai School Of Medicine Office Of Industrial Liason | Methods of determining allergen response using microarray immunoassay techniques |
| MX2011006353A (es) | 2008-12-19 | 2011-07-13 | Merz Pharma Gmbh & Co Kgaa | Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos. |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| GB201104537D0 (en) * | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
| DE102011086048A1 (de) | 2011-04-07 | 2012-10-11 | Continental Teves Ag & Co. Ohg | Gehäuseseitige Trennschicht zur Stressentkopplung von vergossenen Elektroniken |
| WO2014159607A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
| US9492535B2 (en) * | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| US20150320706A1 (en) * | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| AU2015306683B2 (en) | 2014-08-25 | 2021-11-25 | Societe Des Produits Nestle S.A. | Egg protein formulations and methods of manufacture thereof |
| EP3568027A4 (en) | 2017-01-13 | 2020-11-11 | Aimmune Therapeutics, Inc. | WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY |
-
2018
- 2018-11-01 JP JP2020524388A patent/JP7498661B2/ja active Active
- 2018-11-01 CA CA3080601A patent/CA3080601A1/en active Pending
- 2018-11-01 US US16/178,502 patent/US11369676B2/en active Active
- 2018-11-01 MX MX2020004683A patent/MX2020004683A/es unknown
- 2018-11-01 EP EP18871949.6A patent/EP3703743A4/en active Pending
- 2018-11-01 KR KR1020207015239A patent/KR102753602B1/ko active Active
- 2018-11-01 CN CN201880071608.XA patent/CN111344010A/zh active Pending
- 2018-11-01 AU AU2018358125A patent/AU2018358125B2/en active Active
- 2018-11-01 WO PCT/US2018/058777 patent/WO2019089978A1/en not_active Ceased
-
2022
- 2022-05-24 US US17/752,639 patent/US12357688B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018358125A1 (en) | 2020-05-14 |
| US20190167785A1 (en) | 2019-06-06 |
| CA3080601A1 (en) | 2019-05-09 |
| JP7498661B2 (ja) | 2024-06-12 |
| US11369676B2 (en) | 2022-06-28 |
| EP3703743A4 (en) | 2021-12-08 |
| CN111344010A (zh) | 2020-06-26 |
| EP3703743A1 (en) | 2020-09-09 |
| US12357688B2 (en) | 2025-07-15 |
| AU2018358125B2 (en) | 2025-09-04 |
| WO2019089978A1 (en) | 2019-05-09 |
| JP2021501763A (ja) | 2021-01-21 |
| KR20200083526A (ko) | 2020-07-08 |
| KR102753602B1 (ko) | 2025-01-10 |
| US20220288196A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004683A (es) | Metodos de inmunoterapia oral. | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX388380B (es) | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MX372990B (es) | Composiciones para el tratamiento del ojo seco. | |
| MX2017005260A (es) | Bifidobacterias activadas y metodos de uso de las mismas. | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| CA3073829A1 (en) | Methods and compositions for detecting and treating endometriosis | |
| BR112018003110A2 (pt) | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos | |
| MX2016010854A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. | |
| MX384112B (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de enfermedades alergicas. . | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MX2017002134A (es) | Agente para el tratamiento y/o prevencion de enfermedades asociadas con anormalidades inmunes. | |
| MX2016005294A (es) | Metodos para tratar y prevenir enfermedad injerto contra huésped. | |
| WO2015110923A3 (en) | Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia | |
| HRP20190283T1 (hr) | Postupak za verifikaciju radioterapijskog liječenja specifičnog za pacijenta i osiguranje kvalitete | |
| MX2016009306A (es) | Reequilibrado inmunologico epicutaneo. | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| MX385405B (es) | Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. | |
| PH12015502687A1 (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| HK1244692A1 (zh) | 治疗纤维化的方法 | |
| HK1249583A1 (zh) | 作为血液学毒性生物标记之gdf-15 | |
| MX2016002307A (es) | Tratamiento para el cancer. |